UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 105

Sortiert nach

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

Clinical cancer research, 2016-05, Vol.22 (10), p.2351-2358

2016

Link zum Volltext

Verfügbarkeit prüfen

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

Proceedings of the National Academy of Sciences - PNAS, 2015-09, Vol.112 (39), p.E5381-E5390

2015

Link zum Volltext

Verfügbarkeit prüfen

Subtle sequence variations alter tripartite complex kinetics and G-quadruplex dynamics in RNA aptamer Broccoli

Chemical communications (Cambridge, England), 2020-02, Vol.56 (17), p.2634-2637

2020

Link zum Volltext

Verfügbarkeit prüfen

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins

Proceedings of the National Academy of Sciences - PNAS, 2013-11, Vol.110 (48), p.19519-19524

2013

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes

Leukemia, 2018-11, Vol.32 (11), p.2374-2387

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-term potentiation-dependent spine enlargement requires synaptic Ca2+-permeable AMPA receptors recruited by CaM-kinase I

The Journal of neuroscience, 2010-09, Vol.30 (35), p.11565-11575

2010

Link zum Volltext

Verfügbarkeit prüfen

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

EMBO molecular medicine, 2023-10, Vol.15 (10), p.e17367-e17367

2023

Link zum Volltext

Verfügbarkeit prüfen

Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma

Molecular cancer research, 2019-03, Vol.17 (3), p.676-685

2019

Link zum Volltext

Verfügbarkeit prüfen

Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target

Proceedings of the National Academy of Sciences - PNAS, 2013-11, Vol.110 (48), p.19513-19518

2013

Link zum Volltext

Verfügbarkeit prüfen

ROS1-dependent cancers - biology, diagnostics and therapeutics

Nature reviews. Clinical oncology, 2021-01, Vol.18 (1), p.35-55

2021

Link zum Volltext

Verfügbarkeit prüfen

RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation

Disease models & mechanisms, 2021-02, Vol.14 (2)

2021

Link zum Volltext

Verfügbarkeit prüfen

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Communications biology, 2020-12, Vol.3 (1), p.776-776, Article 776

2020

Link zum Volltext

Verfügbarkeit prüfen

Discovery and Validation of a Compound to Target Ewing's Sarcoma

Pharmaceutics, 2021-09, Vol.13 (10), p.1553

2021

Link zum Volltext

Verfügbarkeit prüfen

Critical Role of cAMP-Dependent Protein Kinase Anchoring to the L-Type Calcium Channel Cav1.2 via A-Kinase Anchor Protein 150 in Neurons

Biochemistry (Easton), 2007-02, Vol.46 (6), p.1635-1646

2007

Link zum Volltext

Verfügbarkeit prüfen

Therapeutically Targetable ALK Mutations in Leukemia

Cancer research (Chicago, Ill.), 2015-06, Vol.75 (11), p.2146-2150

2015

Link zum Volltext

Verfügbarkeit prüfen

Functional impact and targetability of PI3KCA , GNAS , and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation

Cold Spring Harbor molecular case studies, 2022-01, Vol.8 (1), p.a006140

2022

Link zum Volltext

Verfügbarkeit prüfen

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer

Clinical cancer research, 2020-06, Vol.26 (11), p.2654-2663

2020

Link zum Volltext

Verfügbarkeit prüfen

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors

Molecular cancer therapeutics, 2022-02, Vol.21 (2), p.336-346

2022

Link zum Volltext

Verfügbarkeit prüfen

ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells

Molecular and cellular biochemistry, 2010-02, Vol.335 (1-2), p.155-171

2010

Link zum Volltext

Verfügbarkeit prüfen

Revisiting NTRKs as an emerging oncogene in hematological malignancies

Leukemia, 2019-11, Vol.33 (11), p.2563-2574

2019

Link zum Volltext

Verfügbarkeit prüfen

A Broccoli aptamer chimera yields a fluorescent K sensor spanning physiological concentrations

Chemical communications (Cambridge, England), 2021-02, Vol.57 (11), p.1344-1347

2021

Link zum Volltext

Verfügbarkeit prüfen

A blast from the past: ROS1 on the brain

Oncotarget, 2019-03, Vol.10 (18), p.1664-1666

2019

Link zum Volltext

Verfügbarkeit prüfen

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions

Clinical cancer research, 2020-06, Vol.26 (12), p.2932-2945

2020

Link zum Volltext

Verfügbarkeit prüfen

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma

Clinical cancer research, 2018-12, Vol.24 (24), p.6471-6482

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(103)

Publikationsform

Artikel
(104)
Dissertationen
(1)

Sprache

Englisch
(104)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(57)
Life Sciences & Biomedicine
(48)
Animals
(36)
Humans
(34)
Oncology
(22)
Rats
(20)
Cell Line, Tumor
(16)
Mice
(16)
Phosphorylation
(15)
Mutation
(14)
Kinases
(12)
Neurosciences
(12)
Neurosciences & Neurology
(12)
Rats, Sprague-Dawley
(12)
Cells, Cultured
(11)
Proteins
(11)
Cell Biology
(10)
Protein Kinase Inhibitors - Therapeutic Use
(10)
Signal Transduction
(10)
Protein Kinase Inhibitors - Pharmacology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

Subtle sequence variations alter tripartite complex kinetics and G-quadruplex dynamics in RNA aptamer Broccoli

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes

Long-term potentiation-dependent spine enlargement requires synaptic Ca2+-permeable AMPA receptors recruited by CaM-kinase I

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma

Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target

ROS1-dependent cancers - biology, diagnostics and therapeutics

RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Discovery and Validation of a Compound to Target Ewing's Sarcoma

Critical Role of cAMP-Dependent Protein Kinase Anchoring to the L-Type Calcium Channel Cav1.2 via A-Kinase Anchor Protein 150 in Neurons

Therapeutically Targetable ALK Mutations in Leukemia

Functional impact and targetability of PI3KCA , GNAS , and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors

ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells

Revisiting NTRKs as an emerging oncogene in hematological malignancies

A Broccoli aptamer chimera yields a fluorescent K sensor spanning physiological concentrations

A blast from the past: ROS1 on the brain

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma

Suchergebnisse filtern